References
- Future reviews [internet]. ALS Untangled. 2023. Available at: https://www.alsuntangled.com/future-reviews/. Accessed July 19, 2023.
- Melmed S, et al. Williams textbook of endocrinology. Chapter 2, Principles of hormone action. 14th ed. Philadephia, PA: Elsevier, 2020.
- Melmed S, et al. Williams textbook of endocrinology. Chapter 33, Physiology of insulin secretion. 14th ed. Philadephia, PA: Elsevier, 2020.
- Melmed S, et al. Williams textbook of endocrinology. Chapter 34, Pathophysiology of diabetes mellitus. 14th ed. Philadephia, PA: Elsevier, 2020
- D’Amico E, Grosso G, Nieves JW, Zanghì A, Factor-Litvak P, Mitsumoto H, et al. Metabolic abnormalities, dietary risk factors and nutritional management in amyotrophic lateral sclerosis. Nutrients 2021;13:2273.
- Guillot S, Bolborea M, Dupuis L. Dysregulation of energy homeostasis in amyotrophic lateral sclerosis. Curr Opin Neurol. 2021;34:773–80.
- Rappoport A. (2023). Insulin in amyotrophic lateral sclerosis: impairment, tests and treatment. Preprints.org.
- Mariosa D, Hammar N, Malmström H, Ingre C, Jungner I, Ye W, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol. 2017;81:718–28.
- Vasta R, D'Ovidio F, Logroscino G, Chiò A. The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurol Sci. 2021;42:1377–87.
- Ahmed R, Phan K, Highton-Williamson E, Strikwerda-Brown C, Caga J, Ramsey E, et al. Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal degeneration. Ann Clin Transl Neurol. 2019;6:486–95.
- Pradat P, Bruneteau G, Gordon P, Dupuis L, Bonnefont-Rousselot D, Simon D, et. Al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler.2010;11:166–71.
- Cistaro A, Pagani M, Montuschi A, Calvo A, Moglia C, Canosa A, et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging. 2014;41:844–52. Epub 2014 Jan 21. PMID: 24445987; PMCID: PMC8957062.
- Pfeiffer RM, Mayer B, Kuncl RW, Check DP, Cahoon EK, Rivera DR, et al. Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:235–45.
- Crossman A, Neary D. Neuroanatomy: an illustrated colour text. 6th ed., Chapter 2. Philadephia, PA: Elsevier, 2020.
- Xing L, Yang S, Cui S, Chen G. Connexin hemichannels in astrocytes: role in CNS disorders. Front Mol Neurosci. 2019;12:23.
- Almad A, Taga A, Joseph J, Gross S, Welsh C, Patankar A, et al. Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS. Proc Natl Acad Sci USA. 2022;119:e2107391119. Report #: ARTN e2107391119. Retrieved from https://escholarship.org/uc/item/7rq3n2jx.
- Leher S, Rehinstein P. Insulin docking within the open hemichannel of connexin 43 may reduce risk of amyotrophic lateral sclerosis. In Vivo. 2023;37:539–47.
- Atilano ML, Grönke S, Niccoli T, Kempthorne L, Hahn O, Morón-Oset J, et al. "Enhanced insulin signaling ameliorates C9orf72 hexanucleotide repeat expansion toxicity in Drosophila. eLife. 2021;10. Gale Academic OneFile, https://gale.com/apps/doc/A656702969/AONE?u=miami_richter&sid=bookmark-AONE&xid=c57fb6dd. Accessed 26 July 2023.
- Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, et. Al. A randomized, double-blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2012;7:e37885.
- Brooke M. Thyrotropin-releasing hormone in ALS. Ann N Y Acad Sci. 1989;553:422–30.
- Lin Y, Sun Z. Thyroid hormone potentiates insulin signaling and attenuates hyperglycemia and insulin resistance in a mouse model of type 2 diabetes. Br J Pharmacol. 2011;162:597–610.
- Clemmons D. The relative role of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest. 2004;113:25–7.
- Nagel G, Peter R, Rosenbohm A, Koenig W, Dupuis L, Rothenbacher D, et al. Association of insulin-like growth factor 1 concentrations with risk for and prognosis of amyotrophic lateral sclerosis-results from the ALS Registry Swabia. Sci Rep. 2020;10:736.
- Beaverd M, Mitchell J, Wokke J, Borasio G. Recombinant insulin-like growth factor 1 rhGF-1)for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2012;11:CD0002064.
- Weinstock, R. General principles of insulin therapy in diabetes mellitus. UpToDate. Retrieved July 26, 2023, from https://www.uptodate.com/contents/general-principles-of-insulin-therapy-in-diabetes-mellitus?search=insulin&source=search_result&selectedTitle=2∼120&usage_type=default#H1050501926
- Pittas, A. Inhaled insulin therapy in diabetes mellitus. UpToDate. Retrieved July 19, 2023, from https://sso.uptodate.com/contents/inhaled-insulin-therapy-in-diabetes-mellitus?search=insulin&topicRef=1752&source=see_link
- Vella, A. Hypoglycemia in adults without diabetes mellitus: determining the etiology. UpToDate. Retrieved July 26, 2023, from https://www.uptodate.com/contents/hypoglycemia-in-adults-without-diabetes-mellitus-determining-the-etiology?search=hypoglycemia&source=search_result&selectedTitle=1∼150&usage_type=default&display_rank=1
- McQueen, H. How much does insulin cost? Here’s how 31 brands and generics compare. GoodRx.com. Retrieved July 26, 202, from https://www.goodrx.com/healthcare-access/research/how-much-does-insulin-cost-compare-brands